American Century Companies Inc. Sells 59,838 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

American Century Companies Inc. lowered its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,079,708 shares of the company's stock after selling 59,838 shares during the period. American Century Companies Inc. owned approximately 0.82% of Centessa Pharmaceuticals worth $18,085,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of CNTA. GAMMA Investing LLC raised its holdings in Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after purchasing an additional 865 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after acquiring an additional 5,316 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Centessa Pharmaceuticals in the third quarter worth about $187,000. Geode Capital Management LLC raised its position in shares of Centessa Pharmaceuticals by 68.7% during the third quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock worth $905,000 after purchasing an additional 23,058 shares during the period. Finally, HighVista Strategies LLC bought a new position in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $737,000. 82.01% of the stock is owned by institutional investors.

Remove Ads

Analysts Set New Price Targets

CNTA has been the topic of several research analyst reports. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating on the stock. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Guggenheim reiterated a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Finally, Piper Sandler started coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals presently has an average rating of "Buy" and an average target price of $27.71.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 11,742 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $16.47, for a total value of $193,390.74. Following the completion of the sale, the insider now directly owns 159,782 shares of the company's stock, valued at $2,631,609.54. This trade represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares of the company's stock, valued at $1,808,271.85. This represents a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 260,168 shares of company stock worth $4,309,568 in the last ninety days. Insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Stock Down 10.6 %

Shares of NASDAQ:CNTA traded down $1.38 during midday trading on Friday, reaching $11.68. The company had a trading volume of 1,581,946 shares, compared to its average volume of 568,524. The business's 50 day moving average price is $16.18 and its 200 day moving average price is $16.33. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $1.56 billion, a PE ratio of -7.63 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.04. Research analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.